FUJIREBIO EUROPE N.V.

Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time... Fujirebio started in Japan in 1950. It developed the first TPHA diagnostics kit, the gold standard for syphilis testing, in 1966. Since then, we have built a strong tradition of innovating, developing, manufacturing and marketing high-quality in vitro diagnostics testing solutions worldwide. Over the years, the acquisition of Centocor Diagnostics, CanAg Diagnostics and Innogenetics have further bolstered our capabilities and expertise in various clinical areas...

VAT numbers: BE 0427.550.660

Primary location: Malvern United States